Imaging Tumor Vascularity and Response to Anti-Angiogenic Therapy Using Gaussia Luciferase

Sci Rep. 2016 May 20:6:26353. doi: 10.1038/srep26353.

Abstract

We developed a novel approach to assess tumor vascularity using recombinant Gaussia luciferase (rGluc) protein and bioluminescence imaging. Upon intravenous injection of rGluc followed by its substrate coelenterazine, non-invasive visualization of tumor vascularity by bioluminescence imaging was possible. We applied this method for longitudinal monitoring of tumor vascularity in response to the anti-angiogenic drug tivozanib. This simple and sensitive method could be extended to image blood vessels/vasculature in many different fields.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage*
  • Animals
  • Cell Line, Tumor
  • Copepoda / enzymology
  • Humans
  • Imidazoles / administration & dosage*
  • Luciferases / metabolism*
  • Luminescent Agents / administration & dosage*
  • Luminescent Measurements
  • Neoplasm Transplantation
  • Neoplasms / blood supply*
  • Neoplasms / drug therapy
  • Neoplasms / metabolism
  • Neoplasms / pathology
  • Phenylurea Compounds / administration & dosage*
  • Pyrazines / administration & dosage*
  • Quinolines / administration & dosage*
  • Recombinant Proteins / administration & dosage
  • Treatment Outcome

Substances

  • Angiogenesis Inhibitors
  • Imidazoles
  • Luminescent Agents
  • Phenylurea Compounds
  • Pyrazines
  • Quinolines
  • Recombinant Proteins
  • tivozanib
  • coelenterazine
  • Luciferases